EGFR and cancer: A number of these resistance mechanisms have been identified in both preclinical and clinical studies and include activation of oncogenic signaling, HGF, VEGF, and PI3K/AKT activation, the latter of which plays a role in de novo resistance and sustenance of EGFR activation in a number of cancers [77, 85, 94–98].